LHI.US's exceptional trend therapy IPO is priced at 4-6 dollars per share, with the planned fundraising amount being increased by 200% to 19 million dollars.

Hong Kong health product sales company Living Homeopathy International Ltd. (referred to as "LHI") expanded the proposed transaction size for its upcoming initial public offering (IPO) last Friday. The company now plans to issue 3.8 million shares at a price of $4-6 per share, raising $19 million. Previously, the company had planned to issue 1.3 million shares at the same price range. The new proposed fundraising scale is 200% higher than before. The company plans to list on NASDAQ under the stock code "LHI". Living Homeopathy International Ltd. was founded in 1994 and is a Hong Kong-based provider of homeopathy services, sourcing homeopathic medications (representing 9% of revenue in the 2024 fiscal year), adjunct medications (representing 80% of revenue in the 2024 fiscal year), and classic flower essences (representing 4% of revenue in the 2024 fiscal year) globally, mainly purchasing from manufacturers and distributing under its own brand "LIVING." Additionally, the company also offers personal care products (such as mouthwash, toothpaste, shampoo, representing 2% of revenue in the 2024 fiscal year) and water filter products (representing 4% of revenue in the 2024 fiscal year), which are developed by the company and manufactured by contracted manufacturers. The company holds a leading position in the Hong Kong homeopathy service market, with a market share of approximately 41% of homeopathy product sales revenue in 2023. Data shows that the company generated revenue of $9 million in the 12 months ending September 30, 2025.